Navigation Links
Opexa Presents Tovaxin Research at Federation of Clinical,Immunology Societies Annual Meeting

ne-year extension study, in which they will receive Tovaxin under an open-label protocol. The open-label study is being planned under a different protocol that will be submitted to the FDA.

About Opexa Therapeutics

Opexa Therapeutics develops and commercializes cell therapies to treat autoimmune diseases such as multiple sclerosis, rheumatoid arthritis, and diabetes. The Company is focused on autologous cellular therapy applications of its proprietary T-cell and stem cell therapies. The Company's lead product, Tovaxin(TM), a T-cell therapy for multiple sclerosis is in Phase IIb trials. The Company holds the exclusive worldwide license for adult multipotent stem cells derived from mononuclear cells of peripheral blood. The technology allows large quantities of monocyte derived stem cells to be produced efficiently for use in autologous therapy, thus circumventing the threat of rejection. The Company is in preclinical development for diabetes mellitus. For more information, visit the Opexa Therapeutics website at www.opexatherapeutics.com.

Safe Harbor Statement

This press release contains "forward-looking statements," including statements about Opexa Therapeutics' growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. These forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Opexa Therapeutics' ability to obtain additional funding, develop its stem cell technologies, achieve its operational objectives, and obtain patent protection for its discoveries, that may cause Opexa Therapeutics' actual results to be materially different from any future results expressed or implied by such forward-looking statements. Opexa Therapeutics undertakes no obligation to update or rev
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Opexa Advances Monocyte Derived Islet Technology to Proof of Principle in stz-induced NOD/SCID Mice
2. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
3. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Dose Escalation Trial with Tovaxin for Multiple Sclerosis
4. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
5. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
6. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
7. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
8. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
9. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
10. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
11. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
Post Your Comments:
(Date:1/23/2015)... analysis of Centers for Medicare and Medicaid Services, (CMS) ... percent of seniors chose lower-cost preferred pharmacy plans that ... The findings were released by Drug Channels . ... of Medicare Part D," said Pharmaceutical Care Management Association ...
(Date:1/23/2015)... a third of reproductive-aged women enrolled in Medicaid, and more ... prescription for an opioid pain medication each year during 2008-2012, ... Weekly Report (MMWR). Opioids are typically prescribed ... They are also found in some prescription cough medications. The ...
(Date:1/23/2015)... baseball,s all-time hits leader, is the new spokesperson for the ... has announced. "Pete,s a Hall of Famer in ... board with Myoflex," said Ducere Pharma Chief Executive Officer ... known across all generations. The passion and intensity that Pete ...
Breaking Medicine Technology:New Analysis: 81 Percent of Medicare Part D Seniors Choose "Preferred Pharmacy" Plans in 2015 2Opioid painkillers widely prescribed among reproductive age women 2Opioid painkillers widely prescribed among reproductive age women 3Pete Rose bets on Myoflex to relieve aches and pains 2
... historic open letter to the World Health Organization ... Drugs (CoMeD) , and the United Methodist Women are seeking ... vaccines.  Currently, the mercury-based preservative Thimerosal, which is 49% mercury ... much of the world, despite the fact that it is ...
... Texas, March 15, 2012  OxySure® Systems, Inc. (OTCBB: ... emergency oxygen solutions with its "oxygen from powder" ... a Supplier Agreement ("Agreement") with W.W. Grainger, Inc. ... (Logo:  http://photos.prnewswire.com/prnh/20120315/DA71084LOGO ) In terms ...
Cached Medicine Technology:Global Call for Mercury-free Vaccines Issued 2OxySure Systems Announces Supplier Agreement With Grainger 2OxySure Systems Announces Supplier Agreement With Grainger 3
(Date:1/22/2015)... LunaDress, with its top dressmaking technologies, has been a leading ... showing its latest designs of wedding dresses and launching a ... CEO, all the fresh new products are designed for 2015, ... 80% off. All the clothes from LunaDress follow up with ...
(Date:1/22/2015)... (PRWEB) January 23, 2015 VogueQueen is a ... affordable prices and many designers are thrilled to have it ... business announces its new collection of prom dresses for the ... to drive the strategic vision and he focuses on continuing ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 The federal court ... the U.S. District Court, Southern District of West Virginia has ... in that proceeding’s first bellwether trial. In an Order dated ... new trial after finding that C.R. Bard had not proven ...
(Date:1/22/2015)... Oceanside,CA (PRWEB) January 22, 2015 For over 20 ... the Oceanside and Vista area has treated just about ... other personal injury circumstances. And for those same twenty-plus years, ... victims of all those injuries with the best possible doctor. ...
(Date:1/22/2015)... Recently, Weddingshe.com has added many trendy Champagne ... highest annual revenues in the past three years. Today, the ... dresses. , According to the sales manager of the company, ... them in 2015. This point can be reflected on the ...
Breaking Medicine News(10 mins):Health News:LunaDress Shows The Latest Styles Of Wedding Dresses In 2015 2Health News:VogueQueen Unveils New Designs of Prom Dresses for 2015 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2
... , ORLANDO, Fla., Nov. 15 , WHAT: ... Association,s Scientific Sessions 2009 , WHERE: ... Orlando, Florida , Scientific Sessions is the premier cardiovascular instructional and ... research will be presented and about 20,000 attendees are expected. , ...
... most likely when new lead is needed in ... (HealthDay News) -- Replacing or adding wiring increases ... surgery to replace a pacemaker or other heart ... researchers analyzed complication rates among patients enrolled in ...
... Three of six platelet reactivity tests predicted a risk of ... anti-clotting drugs following angioplasty (PCI) plus stenting. , -- Three ... may soon be practical to test every PCI-plus-stent patient,s response ... Three platelet function tests all identified heart patients who will ...
... ... to hire in-house graphic designers. Aaron Carr, President and Founder of The Logo Loft firmly ... Carr feels that with the current state of the economy, contracting work outside of the ... as a whole. , ...
... , NEW ORLEANS, Nov. 14 Organizers ... are pleased with its success today. Not only did the ... of some sick individuals. Many of the patients had not ... in 2005. , Volunteer physicians and other medical providers tended ...
... ... to 10 Top Picks per Week on Average & the company,s +120 Betting System which ... No B.S., Scam, or Upsell Tactics the less reputable services use. Subscribers are given ... been updated with that day,s pick(s). , ...
Cached Medicine News:Health News:American Heart Association Late Breaking Clinical Trial Report: Tests Predict Which Patients Are Resistant to Anti-Clotting Therapy During Angioplasty, Stenting 2Health News:American Heart Association Late Breaking Clinical Trial Report: Tests Predict Which Patients Are Resistant to Anti-Clotting Therapy During Angioplasty, Stenting 3Health News:While Most Businesses are Laying-Off Their Employees, The Logo Loft Continues to Hire U.S. Graphic Designers 2Health News:Multiple Health Conditions Discovered During Free Clinic for Uninsured People in New Orleans 2Health News:Picks Network - Offering Free Sports Picks & Top Picks for Life for Only $299 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: